Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial

BACKGROUND: The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney d...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nephrol Dial Transplant
Autors principals: Bhandari, Sunil, Kalra, Philip A, Berkowitz, Mario, Belo, Diogo, Thomsen, Lars L, Wolf, Myles
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
ORIGINAL ARTICLES
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7771981/
https://ncbi.nlm.nih.gov/pubmed/32049331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ndt/gfaa011
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars